Counterparties

MORNING BID – Volatility, or lack thereof

April 23, 2014

It was another disappointing night for those looking for heavy volatility out of those reporting earnings – the trio of biotech stocks many were looking at, Gilead, Illumina and Amgen, had varying results, but they didn’t show the kind of bounce that some people were expecting.

MORNING BID – Biotech swings into earnings

April 22, 2014

Earnings get a bit less boring with a slew of biotechnology and medical device names out Tuesday, most of them after the closing bell.

MORNING BID – A week overflowing with earnings

April 21, 2014

Markets head into a busy week of earnings with a bit of uncertainty around whether the major companies out there will help continue the momentum in the stock market that was regained last week after some weeks of lackluster trading.

MORNING BID: Running on Empty

March 25, 2014

The most interesting developing trend in the U.S. equity market has been the recent stumble in the biotech and momentum-oriented names, be it Gilead Sciences, Biogen, Netflix or a few others. The biotechs were a group often cited as having entered a “parabolic” stage, which in market parlance refers basically to “going up and up and up in a straight line.” The move wasn’t anything on the order of the homebuilders during the housing bubble of 2006 to 2007, or the tech giants during the latter stages of the tech run – a 300 percent gain versus 700 to 800 percent gains back in the other cases. That doesn’t mean we won’t see an ongoing breakdown, though some of the selling abated late in the Monday session.